These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 33180323)

  • 21. Rivaroxaban or vitamin-K antagonists following early endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis.
    Sebastian T; Hakki LO; Spirk D; Baumann FA; Périard D; Banyai M; Spescha RS; Kucher N; Engelberger RP
    Thromb Res; 2018 Dec; 172():86-93. PubMed ID: 30391776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants.
    Prandoni P; Ageno W; Ciammaichella M; Mumoli N; Zanatta N; Imberti D; Visonà A; Bucherini E; Di Nisio M; Noventa F;
    Intern Emerg Med; 2020 Apr; 15(3):447-452. PubMed ID: 31667697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemorrhagic risk and intracranial complications in patients with minor head injury (MHI) taking different oral anticoagulants.
    Spinola MB; Riccardi A; Minuto P; Campodonico P; Motta G; Malerba M; Guiddo G; Lerza R
    Am J Emerg Med; 2019 Sep; 37(9):1677-1680. PubMed ID: 30573225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art.
    Monaco G; Bucherini L; Stefanini B; Piscaglia F; Foschi FG; Ielasi L
    World J Gastroenterol; 2023 Sep; 29(33):4962-4974. PubMed ID: 37731994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment.
    Custo S; Tabone E; Aquilina A; Gatt A; Riva N
    Hamostaseologie; 2024 Aug; 44(4):242-254. PubMed ID: 38354834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
    Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
    PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
    Weitz JI; Jaffer IH
    Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study.
    Turpie AGG; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Ageno W
    Thromb Res; 2017 Jul; 155():23-27. PubMed ID: 28477534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.
    De Stefano V; Qi X; Betti S; Rossi E
    Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.
    Ashley J; McArthur E; Bota S; Harel Z; Battistella M; Molnar AO; Jun M; Badve SV; Garg AX; Manuel D; Tanuseputro P; Wells P; Mavrakanas T; Rhodes E; Sood MM
    Am J Kidney Dis; 2020 Sep; 76(3):311-320. PubMed ID: 32333946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting.
    Nielsen A; Poulsen PB; Dybro L; Kloster B; Lorentzen A; Olsen J; Kümler T
    J Med Econ; 2019 Dec; 22(12):1321-1327. PubMed ID: 31516054
    [No Abstract]   [Full Text] [Related]  

  • 34. Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT).
    Bauersachs R; Gerlach HE; Heinken A; Hoffmann U; Langer F; Noppeney T; Pittrow D; Klotsche J; Rabe E
    Eur J Vasc Endovasc Surg; 2021 Aug; 62(2):241-249. PubMed ID: 34210599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in anticoagulant prescribing: a review of local policies in English primary care.
    Ho KH; van Hove M; Leng G
    BMC Health Serv Res; 2020 Apr; 20(1):279. PubMed ID: 32245380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct oral anticoagulants in patients with liver cirrhosis: A systematic review.
    Hoolwerf EW; Kraaijpoel N; Büller HR; van Es N
    Thromb Res; 2018 Oct; 170():102-108. PubMed ID: 30153564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
    Medina A; Raskob G; Ageno W; Cohen AT; Brekelmans MPA; Chen CZ; Grosso MA; Mercuri MF; Segers A; Verhamme P; Vanassche T; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Thromb Haemost; 2017 Dec; 117(12):2406-2414. PubMed ID: 29212128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban.
    Ferreira T; Huber SC; de Moraes Martinelli B; Junior AL; Menezes FH; Orsi FA; Bittar LF; de Oliveira LFG; Sodre LR; Mello TT; Rielli G; Colella MP; de Paula EV; Yamaguti-Hayakawa GG; Montalvão S; Annichino-Bizzacchi JM
    Vascul Pharmacol; 2020 Jan; 124():106608. PubMed ID: 31678199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.